As of April 29, 2025, Longeveron (LGVN) has a market cap of $23.933 million USD. According to our data, Longeveron is ranked No.8497 in global market value.
Year | Market Cap | %Change |
---|---|---|
Apr 29, 2025 | $23.93 M |
3.60%
|
Dec 31, 2024 | $23.10 M |
-87.28%
|
Dec 29, 2023 | $0.18 B |
-57.76%
|
Dec 30, 2022 | $0.43 B |
-73.32%
|
Dec 31, 2021 | $1.61 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
![]() Mesoblast
MESO
|
$1.51 B |
0.786 M
|
![]() Australia
|
![]() Capricor Therapeutics
CAPR
|
$0.57 B |
0.000 M
|
![]() USA
|
![]() Lineage Cell Therapeutics
LCTX
|
$0.11 B |
0.000 M
|
![]() USA
|
![]() BrainStorm Cell Therapeutics
BCLI
|
$7.08 M |
0.000 M
|
![]() USA
|
![]() Vericel
VCEL
|
$1.97 B |
-0.000 M
|
![]() USA
|
![]() Sangamo Therapeutics
SGMO
|
$0.16 B |
0.000 M
|
![]() USA
|
![]() Fate Therapeutics
FATE
|
$0.13 B |
-0.000 M
|
![]() USA
|
![]() bluebird bio
BLUE
|
$40.34 M |
0.000 M
|
![]() USA
|
![]() Cellectis
CLLS
|
$0.21 B |
48.381 M
|
![]() France
|
![]() Adaptimmune Therapeutics
ADAP
|
$69.44 M |
0.000 M
|
![]() UK
|
![]() CRISPR Therapeutics
CRSP
|
$3.23 B |
-0.000 M
|
![]() Switzerland
|
![]() Editas Medicine
EDIT
|
$0.13 B |
0.000 M
|
![]() USA
|
![]() Intellia Therapeutics
NTLA
|
$0.85 B |
-0.000 M
|
![]() USA
|
Market Cap | = | LGVN Stock Price | * | LGVN Shares Outstanding |
= | $1.60 | * | 13.47 M | |
= | $23.93 M |